Eap CB - Search Results

1

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A; Swiss HIV Cohort Study. Fellay J, et al. Among authors: eap cb. Lancet. 2002 Jan 5;359(9300):30-6. doi: 10.1016/S0140-6736(02)07276-8. Lancet. 2002. PMID: 11809184

2

Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects.

Eap CB, Laurian S, Souche A, Koeb L, Reymond P, Buclin T, Baumann P. Eap CB, et al. Neuropsychobiology. 1992;25(4):214-20. doi: 10.1159/000118840. Neuropsychobiology. 1992. PMID: 1454163

3

Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers.

Eap CB, Schnyder C, Besson J, Savary L, Buclin T. Eap CB, et al. Clin Pharmacol Ther. 1998 Jul;64(1):52-7. doi: 10.1016/S0009-9236(98)90022-4. Clin Pharmacol Ther. 1998. PMID: 9695719

4

Efavirenz decreases methadone blood concentrations.

Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Marzolini C, et al. Among authors: eap cb. AIDS. 2000 Jun 16;14(9):1291-2. doi: 10.1097/00002030-200006160-00036. AIDS. 2000. PMID: 10894303 No abstract available.

5

Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.

Bart PA, Rizzardi PG, Gallant S, Golay KP, Baumann P, Pantaleo G, Eap CB. Bart PA, et al. Among authors: eap cb. Ther Drug Monit. 2001 Oct;23(5):553-5. doi: 10.1097/00007691-200110000-00010. Ther Drug Monit. 2001. PMID: 11591903

6

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Eap CB, Buclin T, Baumann P. Eap CB, et al. Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003. Clin Pharmacokinet. 2002. PMID: 12405865 Review.

7

CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.

Eap CB, Fellay J, Buclin T, Bleiber G, Golay KP, Brocard M, Baumann P, Telenti A. Eap CB, et al. Pharmacogenetics. 2004 Apr;14(4):255-60. doi: 10.1097/00008571-200404000-00005. Pharmacogenetics. 2004. PMID: 15083070

8

Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. Eap CB, et al. Eur J Clin Pharmacol. 2004 Jun;60(4):237-46. doi: 10.1007/s00228-004-0762-z. Epub 2004 Apr 28. Eur J Clin Pharmacol. 2004. PMID: 15114429 Clinical Trial.

9

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.

Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. Eap CB, et al. Eur J Clin Pharmacol. 2004 Jun;60(4):231-6. doi: 10.1007/s00228-004-0767-7. Epub 2004 Apr 28. Eur J Clin Pharmacol. 2004. PMID: 15114431 Clinical Trial.

10

Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.

Eap CB, Jaquenoud Sirot E, Baumann P. Eap CB, et al. Ther Drug Monit. 2004 Apr;26(2):152-5. doi: 10.1097/00007691-200404000-00011. Ther Drug Monit. 2004. PMID: 15228156 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

296 results

Search Page